Anti-Human CD62L - Biotin
| Code | Size | Price |
|---|
| LEI-C2272-100ug | 100 ug | £276.00 |
Quantity:
| LEI-C2272-500ug | 500 ug | £400.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: IgG1
Antibody Clonality: Monoclonal
Antibody Clone: DREG56
Regulatory Status: RUO
Target Species: Human
Application: Flow Cytometry
Shipping:
2-8°C
Storage:
This biotinylated antibody is stable when stored at 2-8°C. Do not freeze.
Further Information
Antigen Distribution:
CD62L is expressed on most circulating leukocytes, including neutrophils, monocytes, T, B and NK cells, and human embryo trophoblasts.
Concentration:
0.5 mg/ml
Conjugate/Tag/Label:
Biotin
Format:
This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This biotinylated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Long Description:
CD62L antibody, clone DREG56, recognizes CD62L, also known as L-selectin or LECAM-1, a 74-95 kDa type I transmembrane glycoprotein and cell adhesion molecule expressed on most circulating leukocytes1. Ligands for CD62L include CD34, GlyCAM-1, and MAdCAM-1, which require sialyation, fucosylation, and carbohydrate sulfation for recognition2,3. Ligand binding mediates tethering and rolling of leukocytes, facilitating entry into secondary lymphoid organs, including lymph nodes and Peyer?s patches, via high endothelial venules (HEVs)1. CD62L is also expressed on human embryo trophoblasts and has been proposed to play a role in human embryo implantation4.
NCBI Gene:
6402
Target:
CD62L
References
1. Ivetic A, et al. (2019) Front Immunol. 10:1068
2. Varki A (1994) Proc Natl Acad Sci USA. 91(16):7390-7397
3. Rosen SD. (1999) Am J Pathol. 155(4):1013-1020
4. Genbacev OD, et al. (1003) Science. 299(5605):405-8
Related Products
| Product Name | Product Code | Supplier | Anti-Human CD62L - APC | LEI-C2273 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-Human CD62L - PE | LEI-C2274 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD62L - PerCP | LEI-C2275 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD62L - DyLight® 488 | LEI-C2276 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD62L - DyLight® 550 | LEI-C2277 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD62L - DyLight® 594 | LEI-C2278 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anti-Human CD62L - DyLight® 650 | LEI-C2279 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||